Alvotech Stock Plummets to New 52-Week Low of $3.00

Alvotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.00 as of June 2, 2026. This significant drop highlights the company's ongoing struggles, with a staggering 79.25% decline in its stock price over the past year, contrasting sharply with the S&P 500's performance of 28.2% during the same period. The company's market capitalization stands at USD 1,192 million, and it currently reports a price-to-earnings (P/E) ratio of 17.00. However, Alvotech's financial metrics reveal underlying weaknesses, including a negative book value and a return on equity of -39.32%. The company's ability to manage its debt is also concerning, as indicated by a poor EBIT to interest ratio of -7.56. Despite a reported annual growth rate of 256.02% in net sales over the last five years, Alvotech's recent financial results show a dramatic decline in profitability, with pre-tax profit falling by 98.94% and net profit down by 99.06% in the latest quarter. The inventory turnover ratio is at a low of 1.17 times, further emphasizing the challenges the company faces in maintaining operational efficiency.